MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality ...
A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer. Association of baseline and on-treatment ctDNA fraction with ...
Spatial transcriptomic analysis of the ImmunoADAPT trial: Neoadjuvant endocrine therapy combined with palbociclib and avelumab in early-stage ER-positive breast cancer. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results